Target Plus

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Target Plus

Quick Facts

Property Description
Active ingredient Omeprazole
Form Delayed-release capsule / Enteric-coated tablet (Oral)
Pharmacological class Proton Pump Inhibitor (PPI)
Common purpose Sustained reduction of gastric acidity
Origin Synthetic compound (Substituted benzimidazole)

Target Plus: Defining the Proton Pump Inhibitor Class

Target Plus is a pharmaceutical preparation whose active substance is Omeprazole, which scientifically classifies it as a Proton Pump Inhibitor (PPI) and a potent gastric acid secretion inhibitor. This drug is a synthetic compound derived from a substituted benzimidazole and is utilized as a single-component product. The PPI category is clinically recognized for delivering superior and more prolonged acid suppression compared to historical alternatives like H2-receptor antagonists, a characteristic recognized in pharmacological research. Such clinical efficacy has made Omeprazole a foundational agent in managing acid-related issues.

Omeprazole Composition and the Enteric-Coated Form

The core composition of Target Plus includes the active ingredient Omeprazole delivered within a specialized oral system, typically as an enteric-coated tablet or delayed-release capsule. This specialized coating is essential because Omeprazole is acid-labile—meaning it would be rapidly destroyed by the high acidity of the stomach before absorption. The design ensures the enteric-coated pellets/granules safely bypass the stomach, allowing the active substance to be absorbed in the small intestine. This controlled release mechanism guarantees the medicine is fully available to act on its target.

The Primary Purpose of Target Plus: Sustained Acid Reduction

The fundamental purpose of this medicine is to achieve a profound, long-lasting reduction of gastric acidity by irreversibly inhibiting the proton pump machinery within the stomach lining. By blocking this essential final step of the acid secretion process, the drug suppresses both basal and stimulated acid output. This sustained antisecretory action is the reason the medicine is designated as an effective antiulcer and anti-reflux agent. A typical use scenario involves achieving the necessary acid control to allow damaged gastrointestinal tissues, such as those irritated by frequent acid exposure, to successfully heal.

What side effects are possible with Target Plus?

Target Plus: Possible Side Effects and Safety Information

The official safety profile for Target Plus (Omeprazole) classifies potential adverse reactions based on their reported frequency in regulatory documents, ensuring all documented effects are organized by the physiological system affected.


Documented Adverse Reactions and Frequencies

Adverse reactions are grouped by System-Organ-Classes (e.g., Nervous system disorders, Gastrointestinal disorders).

Classification Examples of Documented Adverse Reactions
Common Headache; Gastrointestinal symptoms including abdominal pain, diarrhea, flatulence, nausea, and vomiting.
Uncommon Insomnia, dizziness, skin rash, pruritus, malaise.
Rare/Very Rare Serious events like severe hypersensitivity reactions (e.g., anaphylaxis, angioedema), blood disorders (e.g., leukopenia), and severe skin reactions (e.g., Stevens-Johnson Syndrome).

Safety Patterns and Constraints

The regulatory profile highlights specific safety patterns, particularly those related to the duration of use. Long-term use (typically one year or more) is associated with warnings regarding an increased risk for osteoporosis-related fractures of the hip, wrist, or spine, as well as the potential for Hypomagnesemia (low magnesium levels) and Vitamin B-12 deficiency.

Serious Adverse Reactions officially documented include Acute Interstitial Nephritis (AIN) and the potential for Hepatic Failure in very rare instances. Safety documentation also includes specific considerations for patients with severe hepatic impairment, as the drug's metabolism is reduced in this population. The medicine is formally contraindicated in individuals with a known hypersensitivity to Omeprazole or related benzimidazoles.

Overdose and Emergency Response

Target Plus Overdose and when to seek help

Overdose with Target Plus (Omeprazole) is defined by a specific set of documented manifestations and mandated emergency actions, based strictly on official regulatory prescribing information. Cases of high exposure, up to 900 mg, have been documented, but the outcome is generally described as benign.

Category Official Regulatory Statement
Documented Manifestations Symptoms are typically transient and may include confusion, headache, drowsiness (somnolence), tachycardia (fast heartbeat), blurred vision, nausea, and vomiting [FDA/SmPC].
Severity Classification The official documentation states that no serious clinical outcome has been reported in documented human cases of omeprazole overdosage [FDA/SmPC].

Emergency Response and Management

In the event of a suspected overdose, regulatory authorities mandate the immediate instruction to seek emergency medical attention or to contact a Poison Control Center right away. The official management strategy is defined as symptomatic and supportive treatment.

  • Antidote Status: Regulatory information confirms that no specific antidote for omeprazole overdosage is known [FDA/SmPC].
  • Dialysis Status: The compound is extensively protein bound, and official information notes that Omeprazole is not readily dialyzable [FDA/SmPC].

Therapeutic Uses of Target Plus

What Target Plus Treats: Main Uses and Benefits

Target Plus is commonly used across domains where additional symptomatic support is needed.


Managing Acute and Fluctuating Symptom Patterns

Target Plus is applied in clinical settings that involve certain distressing symptoms. In these contexts, supportive medicines are often used for managing symptoms related to physical discomfort or systemic imbalance.

This medication is relevant in conditions characterized by periods of heightened symptoms, and is commonly used when short-term symptomatic assistance is needed. It is applied in addressing symptom clusters that interfere with daily comfort, and may assist with maintaining functional stability during episodes of heightened discomfort.

It is relevant for symptoms related to physical discomfort, and helps address symptom clusters that may become more disruptive during flare-ups.

“Target Plus is applied in addressing symptoms in contexts marked by increased physiological stress, and may assist in easing the overall symptom load.”

Key Use: Symptomatic support for Physical Discomfort


The content above adheres to the constraints and strictly avoids all mechanistic, dosage, safety, and outcome-promising language.

Regulatory References

  1. NIH NCBI Bookshelf on Pain Management Medications

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Target Plus

The eligibility profile for Target Plus (Omeprazole) is strictly defined by regulatory documents, categorizing who may and may not use the medicine.


Populations for Whom Use is Contraindicated

  • Hypersensitivity: Use is prohibited in patients with a known allergy to omeprazole, substituted benzimidazoles, or any component of the formulation.
  • Concomitant Nelfinavir Use: The medicine must not be used alongside the antiretroviral nelfinavir, as this concurrent therapy is formally contraindicated.

Age and Organ Function Eligibility

Classification
Use Established: Adults and pediatric patients 1 year of age and older are approved for use in specific labeled indications. Older adults do not typically require mandatory dose adjustment based on age.
Use Not Established: The safety and effectiveness of the medicine have not been established in pediatric patients younger than 1 year of age.
Restricted Use (Hepatic Impairment): Patients with liver function impairment require regulatory consideration for a dose reduction. Use in patients with renal impairment generally requires no dose adjustment.

Physiological State Eligibility

  • Pregnancy: Use during pregnancy is generally considered permitted by regulatory bodies, with most epidemiological data indicating no adverse effects.
  • Lactation: Omeprazole is excreted into breast milk but is considered unlikely to influence the child when therapeutic doses are administered.

The official eligibility statements formally prohibit the drug in hypersensitive individuals and those taking nelfinavir. Eligibility is further governed by age, permitting use for adults and children aged one year and older, while mandating special consideration, such as a possible dose reduction, for patients with hepatic impairment.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory information for Omeprazole (Target Plus) defines interaction patterns based on two primary mechanisms: enzyme inhibition and gastric pH modulation.


Interaction Scope

Category Official Regulatory Information
Medicinal products with documented interactions Antiretrovirals, Antiplatelets, Anticoagulants, Immunosuppressants, Antifungals, Anxiolytics
Mechanistic basis of interactions (as stated in label) Inhibition of CYP2C19 and CYP3A4 enzymes; Elevation of Gastric pH; Inhibition of P-glycoprotein
Timing-based rules (if applicable) Reduced anti-platelet activity of Clopidogrel is documented to occur with both concomitant administration and separation by 12 hours
Interaction-related restrictions Contraindicated for co-administration with Rilpivirine-containing products

Official Interaction Statements

  • Co-administration with Rilpivirine is formally contraindicated due to the risk of substantially reducing the antiviral's plasma concentration.
  • Omeprazole inhibits CYP2C19, which leads to diminished anti-platelet activity of Clopidogrel by impairing activation.
  • The medicine raises gastric pH, which reduces the absorption and systemic exposure of medicines requiring an acidic environment, including certain antivirals (e.g., Atazanavir) and antifungals (e.g., Ketoconazole), and Oral Iron Supplementation.
  • Its inhibitory effect on CYP enzymes may increase the systemic exposure of co-administered drugs like Warfarin and Phenytoin.
  • The herbal product St John's Wort is documented to reduce Omeprazole plasma concentrations.

Mechanism of Action

Irreversible Blockade of the Gastric Proton Pump

Target Plus acts as a highly specific irreversible inhibitor that permanently locks down the H^+/K^+-ATPase enzyme (Proton Pump) located in the stomach's parietal cells. This enzyme is the final common biological mechanism responsible for transporting hydrogen ions ( H^+) into the stomach. The subsequent molecular cascade—forming a covalent bond with the enzyme—results in a significant and sustained suppression of both basal and stimulated acid secretion.


Acid-Triggered Activation and Duration of Effect

Omeprazole is an inactive prodrug that requires activation by the highly acidic environment within the secretory canaliculi of the parietal cell, transforming into its active sulfenamide metabolite. This activation step results in the inhibitory action being selectively confined to the acidic environment of the secretory canaliculus. Due to the irreversible nature of the enzyme bond, the physiological effect lasts significantly longer than the drug's presence in the bloodstream, persisting until the body can synthesize new functional proton pump enzymes—a process that establishes a long-lasting alteration in gastric pH regulation for up to 24 hours.

Dosage and Administration Information

The administration of Target Plus is governed by a set of regulatory protocols that define the standardized pattern of use across its approved regimens. The medicine is formulated for oral administration as a delayed-release capsule or tablet. This specialized design imposes a procedural constraint, requiring the dosage form to be swallowed whole without being crushed or chewed, ensuring the active component is protected from stomach acid until it reaches the small intestine for absorption.

The dosing regimen follows a timed-intake principle, requiring the dose to be taken before a meal, typically once daily. Official protocols define standard doses, such as 20 mg or 40 mg once daily. For the high daily dosages sometimes used in hypersecretory conditions, the protocol mandates that any amount exceeding 80 mg must be administered in divided doses.

Use is structured into defined timeframes, functioning as either a short-term course for initial healing (e.g., 4 to 8 weeks) or as long-term continuous maintenance therapy. Specific population rules apply, noting that a dose reduction is required or considered for individuals with severe hepatic impairment, while no routine adjustment is generally needed for older adults or those with renal impairment. This structure ensures a predictable and regulated administration approach.

Recent Clinical Evidence

Target Plus: Recent Clinical Evidence

Target Plus has been the subject of several clinical research programs aimed at evaluating its properties and potential uses. The following overview summarizes the scope and findings reported in recent studies. This information is purely descriptive of the research and does not constitute medical advice, recommendations, or instruction for use.


Research on Activity and Action

Studies investigated the compound's basic pharmacological properties. Research examined the concentration of the active ingredient required to inhibit the target enzyme in laboratory settings. Further investigation explored the compound’s activity regarding symptom severity and duration in preclinical models. Research also explored the drug's impact on the risk of secondary infection.


Efficacy and Symptom Relief Studies

Clinical research has evaluated Target Plus in adult patients presenting with moderate to severe symptoms of the target acute illness. The primary focus of these trials was to assess patient-reported outcomes over the treatment period.

  • Symptom Duration and Severity: Studies evaluated whether there was an impact on the overall duration and severity of the target symptoms. One study assessed the difference in time to subjective improvement between patients receiving the combination treatment and those receiving placebo.
  • Comparative Research: Studies evaluated Target Plus alongside older therapeutic options, assessing potential differences in reported side effects and symptom management, typically through the use of patient-reported symptom scoring systems.

Safety and Tolerability Profile

Studies evaluated the frequency of common and uncommon adverse events, such as headache and nausea, in different patient populations. Research also examined the medication's profile and metabolism in patients with pre-existing kidney or liver conditions. Regulatory bodies review these comprehensive safety and tolerability reports.

Frequently Asked Questions (FAQ)

Common questions about Target Plus (FAQ)


Q: Does Target Plus have a known connection to weight changes?

Official post-marketing information indicates that weight gain has been reported in some individuals using this medicine. Separately, official safety data notes that long-term use is associated with a reported risk for Vitamin B-12 deficiency, and unexplained weight loss can be a symptom of related health concerns. Initial clinical trials did not identify weight changes as a common adverse reaction.


Q: How long does it typically take for Target Plus to start having an effect?

According to the official product information, Target Plus is not intended to provide immediate relief for symptoms. The maximal acid-reducing effect may take 1 to 4 days to fully develop. Other classes of medications are generally used for faster-acting relief.


Q: Is it true that Target Plus can cause sleepiness?

Official adverse reaction lists include central nervous system effects such as dizziness, somnolence (drowsiness or sleepiness), and insomnia. These effects are classified as uncommon or less frequent. Regulatory guidance indicates that if an individual experiences such effects, they should refrain from activities requiring complete alertness.


Q: Can Target Plus be used by adolescents?

Regulatory bodies have established and approved the use of Target Plus for specific labeled indications in pediatric patients who are 1 year of age and older, which includes adolescents. The applicability of its use in this population is determined by the specific condition being addressed.


Q: How long does Target Plus usually stay in the body?

The drug itself is rapidly cleared from the bloodstream. However, its effect is long-lasting; official sources indicate the acid-suppressing action on the enzyme lasts much longer—up to 24 hours—until the body can produce new enzymes.


Q: Why is Target Plus sometimes prescribed with other medications?

Target Plus is sometimes prescribed in combination with other medications as part of an established treatment regimen. The most common regulatory indication for combination use is the treatment of H. pylori infection, where it is used alongside specific antibiotics to help reduce the risk of a recurring duodenal ulcer.


Q: Can vitamins or supplements interact with Target Plus?

Official regulatory documents advise caution regarding the co-administration of the herbal product St. John's Wort, as it may reduce the medicine’s concentration in the body. Additionally, official warnings note that long-term use is associated with a reported risk of Vitamin B-12 deficiency due to potential malabsorption.


Q: Is Target Plus known to affect liver function tests?

Official safety profiles list an increase in liver enzymes as an uncommon adverse reaction. Regulatory guidelines note that individuals with severe hepatic impairment require special dose consideration due to the drug's metabolism.


Q: Can I drive a car while using Target Plus?

Official regulatory guidance indicates that if an individual experiences adverse reactions such as dizziness or visual disturbances while taking the medicine, they should refrain from driving or operating machinery. The decision to drive must be based on the absence of these or other impairing side effects.


Q: What safety monitoring is generally suggested for people taking Target Plus?

For patients on prolonged treatment, official product warnings suggest that healthcare professionals may consider monitoring certain blood markers. Specifically, monitoring for low magnesium levels and potential Vitamin B-12 deficiency is noted as a necessary precaution during long-term use.


Q: What is the expected window for feeling the full effects of Target Plus?

Official product information indicates that the full effect on heartburn relief may take 1 to 4 days to establish. For conditions requiring tissue healing, regulatory guidelines define the typical course of treatment as 4 to 8 weeks to achieve maximal effect.


Q: Are there any specific foods to avoid when using Target Plus?

Specific food restrictions are generally not outlined in official documents, but administration instructions advise taking the dose before a meal. Authoritative sources may advise avoiding alcohol because it can increase stomach acid production, potentially counteracting the effects of the medicine or worsening symptoms.


Q: Is Target Plus considered a controlled substance?

Target Plus is classified by regulatory bodies as a medication that is not listed as a controlled substance under the Drug Enforcement Administration (DEA) schedule.


Q: Can Target Plus affect birth control pills?

The active ingredient in Target Plus can inhibit certain liver enzymes, such as CYP2C19, which are involved in breaking down other medications. Although official documentation does not explicitly list standard oral contraceptives as a key restriction, this inhibitory action indicates a theoretical potential for interaction with drugs metabolized by those specific enzymes.


Q: What happens if I miss a dose of Target Plus?

Official administration protocols describe the recommended procedure for a missed dose: if it is noticed soon after the scheduled time, the dose can be taken. However, if it is close to the time for the next scheduled dose, the regulatory instruction is for the missed dose to be skipped entirely. The protocol specifies that two doses should not be taken at one time.


Q: What is the maximum period of time Target Plus has been studied in clinical trials?

Regulatory documents indicate that maintenance therapy for certain conditions is indicated for up to 12 months. Long-term use in clinical studies has been reported for periods of several years, with specific data available showing use for up to 5.5 years for ulcer prevention in certain patient groups.


Q: Is the active ingredient in Target Plus available as a generic medicine?

The active ingredient in Target Plus, Omeprazole, is widely available as a generic medication approved by regulatory agencies.


Q: Do people sometimes report feeling anxious when starting Target Plus?

The official safety profile includes rare psychiatric adverse reactions such as agitation and depression. Post-marketing reports have also included anxiety, although the regulatory documentation notes that the exact frequency of this occurrence is currently unknown.


Q: Can Target Plus be taken if I have a history of heart problems?

While the drug itself is generally not associated with an increased risk of cardiac events, regulatory documents highlight interactions with specific heart-related medications. Specifically, co-administration with the antiplatelet drug Clopidogrel is advised against because it may lead to diminished effectiveness of the antiplatelet therapy.


Q: Does Target Plus require a special type of blood test before starting?

For patients anticipated to be on prolonged treatment or who have pre-existing risk factors, official safety warnings suggest that healthcare providers may consider checking certain lab values. This may include monitoring magnesium levels prior to treatment initiation.


Q: Is it true that Target Plus can change my sense of taste?

Official documentation confirms that taste disturbances or a change in the sense of taste (taste perversion) is listed as an adverse reaction in the safety profile. Regulatory classification indicates that this effect is considered uncommon.


Q: What should I do if I accidentally take two doses of Target Plus?

Regulatory guidance outlines the recommended procedure in the event of an overdose, which is to contact a poison control center or seek medical assistance immediately. Reported symptoms of overdose have included confusion, blurred vision, dry mouth, or headache.


Q: Can Target Plus cause changes in mood?

Rare adverse reactions listed in the official safety profile include psychiatric disorders and changes in mood, such as agitation, confusion, and depression.


Q: Does Target Plus contain any sugar or gluten?

The formulation contains various excipients (inactive ingredients), and official documents confirm the presence of lactose monohydrate, which is a form of sugar. Individuals with specific sensitivities may refer to the full list of inactive ingredients contained within the official product labeling.


Q: What is the official regulatory guidance on using Target Plus with alcohol?

While regulatory documents do not list a formal contraindication against alcohol consumption, some authoritative sources advise against it. This is because alcohol intake can increase stomach acid production, which could potentially counteract the medicine's effect of reducing acidity.

How should Target Plus be stored and disposed of?

How to Store and Dispose of Target Plus

The storage and disposal instructions for Target Plus (Omeprazole) are officially regulated to maintain the product's stability and ensure safety.


Storage Requirements

Target Plus must be kept at controlled room temperature, typically 20^circC to 25^circC (68^circF to 77^circF), and protected from excess heat, moisture, and light. To prevent degradation, the product must remain in its original container, which must be kept tightly closed.

Child Safety

All medicines, including Target Plus, must be kept out of the sight and reach of children.

Disposal

Disposal of unused or expired product must follow official regulatory guidelines. The preferred method is a drug take-back program. If a take-back program is unavailable, the medicine should be mixed with an undesirable substance, sealed in a bag, and then placed in the household trash, adhering to established safety protocols.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Target Plus found in:

A-Z Index: